Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Over half of refractory AML patients responded to combo

Advani A et al. ASH 2017, Abstract 150.

Key clinical point: MEC plus ixazomib is well tolerated and effective in relapsed/refractory AML.

Major finding: The overall response rate was 53%.

Study details: A phase 1 trial involving 30 patients.

Disclosures: Dr. Advani reported receiving research funding from Takeda/Millenium, and serving as a consultant for Pfizer.

Source: Advani A et al. ASH 2017, Abstract 150.

Read the full article.

Citation:

Advani A et al. ASH 2017, Abstract 150.

This Week's Must Reads

CVD Events Prevented with New AHA BP Guideline, Circulation; ePub 2018 Nov 19; Bress, et al

USPSTF: Interventions to Prevent Child Maltreatment, JAMA; 2018 Nov 27; US Preventive Services Task Force

Team-Based Primary Care in Chronically Ill Patients, JAMA Intern Med; ePub 2018 Nov 26; Meyers, et al

Rotating Night Shift Work & Risk of T2D, BMJ; ePub 2018 Nov 21; Shan, Li, et al

PUFAs for Primary & Secondary CVD Prevention, Cochrane Library; ePub 2018 Nov 27; Abdelhamid, et al

Must Reads in Oncology

Does Vitamin D Reduce Cancer & CVD Risk?, N Engl J Med; ePub 2018 Nov 10; Manson, et al

Interventions to Increase CRC Screening Rates, JAMA Intern Med; ePub 2018 Oct 15; Dougherty, et al

Smoking & Lung Cancer Mortality in the US to 2065, Ann Intern Med; ePub 2018 Oct 9; Jeon, et al

Dietary Indexes and Risk of Colorectal Cancer, Am J Clin Nutrit; ePub 2018 Oct 4; Petimar, et al

FIT Performance & Optimal Positivity Thresholds, Ann Intern Med; ePub 2018 Sep 18; Selby, et al